Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Selinexor Combined With Daratumumab and Dexamethasone (XDd) for the Treatment of Patients With Advanced Light-Chain Cardiac Amyloidosis: A Prospective, Multicenter, Phase II Clinical Study

NCT07743957 is registered in ClinicalTrials.gov with Beijing Anzhen Hospital as lead sponsor.

NCT NCT07743957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07743957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Selinexor Combined With Daratumumab and Dexamethasone (XDd) for the Treatment of Patients With Advanced Light-Chain Cardiac Amyloidosis: A Prospective, Multicenter, Phase II Clinical Study
Lead sponsor
Beijing Anzhen Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 13, 2026
Completion date
June 1, 2028
Enrollment
63 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

light-chain cardiac amyloidosis